Notes:  May 26, 2015 -- AbbVie (NYSE: ABBV) has completed the acquisition of Pharmacyclics, Inc. (Nasdaq: PCYC) enhancing AbbVie's scientific and commercial presence in oncology. Pharmacyclics will be a wholly-owned subsidiary of AbbVie and will operate from its previous Sunnyvale, Calif. headquarters. Pharmacyclics stockholders who elected to receive the mixed consideration will receive the mixed consideration, which consists of $152.25 in cash and 1.6639 shares of AbbVie common stock per share of Pharmacyclics common stock; Pharmacyclics stockholders who elected to receive the all-cash consideration will receive $261.25 in cash per share of Pharmacyclics common stock; and Pharmacyclics stockholders who elected to receive the all-stock consideration will be subject to proration at a rate of approximately 61.66%, and will receive their consideration in the form of $261.25 in cash for shares not accepted for the all-stock election due to proration and 3.9879 shares of AbbVie common stock per share of Pharmacyclics common stock for shares that were accepted for the all-stock election.

Company's Online Information Links

HOME PAGE:     http://www.pcyc.com/
Company's Investor Relations Information	Goto Investor Relations Information
Company's Online News Releases	Goto News Releases
Online Company Profile	Goto Online Profile

Company's Online SEC EDGAR Filings

Company's SEC EDGAR Filings

Goto SEC Filings

Company's Email Address Links

Email Address	info@pcyc.com
Email Contact Form on Website	Goto Email Form

Address and Phone Numbers

Address:   995 East Arques Avenue, Sunnyvale, CA 94085
Main Phone Number	408-774-0330
Fax Number	408-774-0340
Investor Relations   Ramses Erdtmann - rerdtmann@pcyc.com	408-215-3325
Toll Free Phone Number	Unknown

CEO - Robert W. Duggan

PFO - Rainer M. Erdtmann